One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib

INTRODUCTION: This study evaluated 12 months adherence and persistence among Janus kinase inhibitors (upadacitinib, baricitinib, tofacitinib) and adalimumab, a tumor necrosis factor inhibitor (TNFi), in patients with rheumatoid arthritis (RA). METHODS: This retrospective analysis used administrative...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, Martin, Chen, Naijun, Thielen, Richard, Zueger, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499920/
https://www.ncbi.nlm.nih.gov/pubmed/37542646
http://dx.doi.org/10.1007/s12325-023-02619-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499920/
https://www.ncbi.nlm.nih.gov/pubmed/37542646
http://dx.doi.org/10.1007/s12325-023-02619-6

Ejemplares similares